本次业绩说明会以网络互动形式召开，公司将针对 2023 年半年度的经营成 果、财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 证券代码：603102 证券简称：百合股份 公告编号：2023-045 威海百合生物技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 9 月 21 日（星期四）16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问。公司将在业绩说明会上对投资者普遍关注的问 题进行回答。 威海百合生物技术股份有限公司（以下简称"公司"）已于 2023 年 8 月 9 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 9 月 22 日（星期五）下午 15:00-16:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交 ...

证券代码：603102 证券简称：百合股份 公告编号：2023-044 威海百合生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 二、实施回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司截至 2023 年 8 月 31 日的回购 股份进展情况公告如下： 截至 2023 年 8 月 31 日，公司尚未通过集中竞价交易方式回购公司股份。 上述回购股份进展符合相关法律法规的规定及公司回购股份方案的要求。 1 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号—回购股份》等相关规定及公司回购股份方案，在回购期限内根 据市场情况择机做出回购决策并予以实施，并根据回购股份事项进展情况及时履 行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 ● ...

证券代码：603102 证券简称：百合股份 公告编号：2023-043 威海百合生物技术股份有限公司 重要内容提示： 股东持股的基本情况 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至本公告披露之日，广发信德投资管理有限公司（以下简称"广发信德"） 持有威海百合生物技术股份有限公司（以下简称"公司"）股份 644,100 股，占公 司总股本的 1.01%，上述股份全部来源于公司首次公开发行股票前已持有的股份。 减持计划的实施结果情况 公司于 2023 年 2 月 9 日披露了《关于公司监事及股东减持股份计划公告》 （公告编号：2023-008），广发信德计划通过集中竞价、大宗交易或协议转让等方 式减持公司股份不超过 1,920,000 股，不超过公司总股本的 3%，具体内容详见公 告。截至本公告披露之日，广发信德通过大宗交易方式累计减持公司股份 1,216,000 股，占公司总股本的 1.90%；通过集中竞价方式累计减持公司股份 639,900 股，占公司总股本的 1.00%，广发信德本次 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 20% year-over-year growth[1]. - The company's revenue for the first half of 2023 reached ¥447,916,740.91, representing a 36.55% increase compared to ¥328,035,576.35 in the same period last year[21]. - Net profit attributable to shareholders was ¥97,463,773.26, up 36.00% from ¥71,665,540.30 year-on-year[21]. - The net profit after deducting non-recurring gains and losses was ¥90,032,056.33, a 31.76% increase from ¥68,329,583.25 year-on-year[21]. - The company's operating profit for the first half of 2023 was CNY 112,184,931.72, an increase of 33.8% compared to CNY 83,865,210.09 in the same period of 2022[145]. - The company achieved a revenue of 447.92 million RMB, representing a year-on-year growth of 36.55%[62]. - The net profit for the first half of 2023 was CNY 97,463,773.26, representing a 36.1% increase from CNY 71,665,540.30 in the previous year[142]. Market Expansion and Product Development - User data indicates that the active user base has expanded to 1.2 million, a 15% increase compared to the same period last year[1]. - New product launches are expected to contribute an additional RMB 100 million in revenue, with a focus on health supplements and nutritional products[1]. - The company is focused on expanding its market presence and enhancing product development in the sports nutrition sector[12]. - The company is focusing on developing new products in the categories of infant supplementary food, sports nutrition, and special medical purpose formula foods to meet diverse consumer needs[30]. - The company plans to enhance the development of infant supplementary foods and sports nutrition products to strengthen its competitive advantage[55]. Research and Development - The company is investing in R&D, allocating RMB 50 million for the development of new technologies in the health and wellness sector[1]. - The company has increased R&D expenses to 14.24 million RMB, reflecting a growth of 42.75% as part of its focus on innovation[62]. - The company reported a significant increase in research and development expenses, which rose to CNY 14,243,384.96 from CNY 9,977,841.51, marking a 42.6% increase[141]. Strategic Acquisitions and Investments - The company has completed a strategic acquisition of a local competitor for RMB 200 million, enhancing its product portfolio and distribution network[1]. - The company invested CNY 50,000,000.00 in cash for investments in the first half of 2023, compared to CNY 20,000,000.00 in the same period last year, indicating a 150% increase[148]. Financial Integrity and Compliance - The management emphasizes the importance of maintaining financial integrity and transparency in reporting, ensuring all disclosures are accurate and complete[1]. - The company has maintained a strong capital reserve with total equity reaching CNY 1,489,444,505.84, up from CNY 1,430,680,405.33, reflecting a growth of 4.1%[138]. - The company operates under two main sales models: contract manufacturing and self-owned brands, with a focus on both online and offline distribution channels[41][43]. Risk Management - The company has identified potential risks related to market competition and regulatory changes, which may impact future performance[1]. - The company is actively involved in the regulatory environment, adapting to new guidelines and standards in the health food industry to ensure compliance and market relevance[27]. Shareholder and Governance Matters - The board has approved a profit distribution plan, although no specific dividend has been declared for this period[1]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of 2023[73]. - There were changes in senior management, with Liu Haitao elected as a non-independent director and Tang Dongdong appointed as the financial director[71]. - The company has committed to not transferring or managing shares held by major shareholders for 36 months post-IPO[79]. Operational Efficiency - The company has a robust supply chain management system that includes safety stock for bulk raw materials to ensure stable production operations[36]. - The company adopts a "stock production + sales-based production" model, ensuring timely order fulfillment during peak sales seasons[39]. - The company has established a comprehensive production capacity for various dosage forms, including soft capsules, hard capsules, tablets, powders, oral liquids, and bottled drinks[30]. Certifications and Quality Control - The company maintains various certifications, including ISO9001 and HACCP, ensuring compliance with quality and safety standards[20]. - The company has established a strict quality control system and has received 12 certifications, including ISO9001 and FDA registration, ensuring product safety and reliability[52]. Share Capital and Structure - The total share capital increased from 48,000,000 shares before the IPO to 64,000,000 shares after the IPO, with 14,291,366 shares released from restrictions on February 7, 2023, accounting for 22.33% of the total share capital[114]. - The proportion of restricted shares decreased from 75% to 52.67% after the release of restricted shares, while the proportion of unrestricted circulating shares increased from 25% to 47.33%[112]. Financial Instruments and Accounting Policies - The company recognizes financial assets at fair value with changes in profit or loss for those not classified as amortized cost or fair value through other comprehensive income[194]. - The company applies the expected credit loss model to loan commitments and financial guarantee contracts, measuring impairment based on the higher of the determined loss provision and the initial recognition amount[195].

二、董事会会议审议情况 与会董事经认真审议和表决，通过如下决议： （一）审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 威海百合生物技术股份有限公司（以下简称"公司"）于 2023 年 7 月 29 日 向各位董事发出了召开第四届董事会第五次会议的通知。2023 年 8 月 8 日，第 四届董事会第五次会议以通讯和现场投票相结合的表决方式在公司会议室召开， 应出席本次会议的董事 9 人，实际出席本次会议的董事 9 人，公司相关高级管理 人员列席了本次会议。本次会议由董事长刘新力召集和主持，会议的召开符合有 关法律、行政法规、部门规章、规范性文件和《公司章程》的有关规定。 证券代码：603102 证券简称：百合股份 公告编号：2023-040 威海百合生物技术股份有限公司 第四届董事会第五次会议决议公告 2023 年 8 月 9 日 表决结果：9 票同意，0 票反对，0 票弃权 具体内容详见公司于上海证券交易所网站（www.sse.com.cn ...

证券代码：603102 证券简称：百合股份 公告编号：2023-042 威海百合生物技术股份有限公司 关于公司 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 经中国证券监督管理委员会证监许可[2022]36 号文核准，本公司于 2022 年 1 月向社会公开发行人民币普通股（A 股）1,600.00 万股，每股发行价为 42.14 元，募集资金总额为人民币 67,424.00 万元，根据有关规定扣除发行费用 7,180.89 万元后，实际募集资金金额为 60,243.11 万元。该募集资金已于 2022 年 1 月到 账，上述资金到账情况业经容诚会计师事务所容诚验字[2022]251Z0001 号《验资 报告》验证，公司对募集资金采取了专户存储管理。后因证券登记费减免 6.40 万 元，实际发行费用较之前减少 6.40 万元，募集资金净额实际为 60,249.51 万元。 （二）本年度使用金额 ...

证券代码：603102 证券简称：百合股份 公告编号：2023-041 威海百合生物技术股份有限公司 威海百合生物技术股份有限公司（以下简称"公司"）于 2023 年 7 月 29 日向 各位监事发出了召开第四届监事会第四次会议的通知。2023 年 8 月 8 日，第四 届监事会第四次会议以通讯和现场投票相结合的表决方式在公司会议室召开，应 出席本次会议的监事 3 人，实际出席本次会议的监事 3 人，监事会主席刘禄增先 生主持会议，会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的有关规定。 二、监事会会议审议情况 与会监事经认真审议和表决，通过如下决议： （一）审议通过了《关于公司 2023 年半年度报告及其摘要的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 监事会认为，董事会编制和审核 2023 年半年度报告及其摘要的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上市公 司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 （二）审议通过了《关于公司 2023 年半年度募集资金存放与实际使用情况 专项报告的议案》 第四届监事会第四次会议决 ...

独立董事关于第四届董事会第五次会议相关事项的 威海百合生物技术股份有限公司 独立意见 根据《上市公司独立董事规则》《上市公司治理准则》《上海证券交易所股 票上市规则》等法律、法规以及《公司章程》和公司《独立董事工作细则》的有 关规定,我们作为威海百合生物技术股份有限公司(以下简称"公司")的独立 董事,本着认真、负责、实事求是的态度,对公司第四届董事会第五次会议相关 事项的独立意见如下: 一、关于公司 2023年半年度募集资金存放与实际使用情况的专项报告的独 立意见 我们认为,《关于公司 2023年半年度募集资金存放与实际使用情况的专项 报告》真实地反映了公司募集资金存放、使用与管理的情况,公司募集资金的存 放和实际使用情况符合《上市公司监管指引第2号 -- 上市公司募集资金管理和 使用的监管要求》《上海证券交易所上市公司自律监管指引第1 号 -- 规范运作》 等有关规定。公司对募集资金进行了专户存储和专项使用,并及时履行了相关信 息披露义务,募集资金实际使用情况与公司信息披露情况不存在差异,不存在募 集资金存放和使用违规的情形。 (以下无正文,转签字页) (本页无正文,为威海百合生物技术股份有限公司独立董事 ...

证券代码：603102 证券简称：百合股份 公告编号：2023-028 威海百合生物技术股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2023 年 4 月 18 日（星期二）16:00 前通过公司邮箱 suntongbo@sohu.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 威海百合生物技术股份有限公司（以下简称"公司"）已于 2023 年 4 月 7 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况及利润分配，公司计划于 2023 年 4 月 19 日下午 15:00-16:00 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交 流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度的经营成果、 财务指标及利润分配的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥231,965,285.09, representing a year-on-year increase of 58.73%[3] - The net profit attributable to shareholders for the same period was ¥44,783,221.82, reflecting a growth of 43.99% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥43,663,071.25, up by 47.28% year-on-year[3] - The basic earnings per share for Q1 2023 was ¥0.70, an increase of 32.08% from the same period last year[3] - Operating profit for Q1 2023 was ¥51,434,864.07, up 42.5% from ¥36,134,571.23 in the same period last year[16] - Net profit attributable to shareholders for Q1 2023 was ¥44,783,221.82, representing a 43.5% increase from ¥31,101,485.21 in Q1 2022[16] - Basic and diluted earnings per share for Q1 2023 were both ¥0.70, compared to ¥0.53 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,691,268,320.85, which is a 1.76% increase from the end of the previous year[3] - As of March 31, 2023, the company's total assets amounted to ¥1,691,268,320.85, an increase from ¥1,661,982,995.88 as of December 31, 2022, reflecting a growth of approximately 1.4%[12] - The company's total current assets reached ¥1,335,435,966.94, compared to ¥1,307,447,191.14 at the end of 2022, indicating an increase of about 2.1%[12] - Total liabilities decreased to ¥224,435,937.28 from ¥239,933,834.13, a reduction of approximately 6.4%[14] - The company's equity attributable to shareholders increased to ¥1,466,832,383.57 from ¥1,422,049,161.75, reflecting a growth of about 3.1%[14] Cash Flow - The cash flow from operating activities showed a net outflow of ¥10,261,019.33, a decrease of 24.10% compared to the previous year[3] - Cash flow from operating activities for Q1 2023 was ¥10,261,019.33, down 24.5% from ¥13,518,587.35 in Q1 2022[19] - The company reported a net cash outflow from investing activities of ¥65,853,894.83 in Q1 2023, compared to a net outflow of ¥13,860,848.35 in Q1 2022[19] - The company experienced a net cash inflow from financing activities of ¥604,672,519.48 in Q1 2023, with no comparable figure reported for Q1 2022[19] Expenses - The company's research and development expenses increased by 41.69%, indicating a rise in investment in innovation[6] - Research and development expenses for Q1 2023 amounted to ¥6,765,422.11, up 41.7% from ¥4,774,889.11 in Q1 2022[15] - The company's financial expenses surged by 184.42%, primarily due to an increase in bank deposit balances and interest income[6] - Total operating costs for Q1 2023 were ¥175,042,448.36, an increase of 61.2% from ¥108,512,966.16 in Q1 2022[15] Accounts Receivable and Payable - The company reported a significant increase in accounts receivable by 41.90%, attributed to revenue growth[6] - Accounts receivable rose to ¥46,607,305.17, up from ¥32,844,069.92, marking an increase of around 42%[12] - The company reported a decrease in accounts payable to ¥94,966,301.36 from ¥98,628,162.51, a decline of approximately 3.4%[13] Other Information - The number of ordinary shareholders at the end of the reporting period was 8,549[8] - The company has not disclosed any new product or technology developments in this quarter[10] - There are no significant mergers or acquisitions reported during this period[10] - The company announced the implementation of new accounting standards starting in 2023, which will affect the financial statements from the beginning of the year[20]